Cancer Treatment Reviews
Volume 27, Issue 4 , Pages 247-255 , August 2001

Dendritic cell vaccines for cancer therapy

  • G.M. Sprinzl

      Affiliations

    • Department of Otorhinolaryngology – Head and Neck Surgery
    • ,
  • L. Kacani

      Affiliations

    • Institute of Hygiene and Social Medicine
    • ,
  • A. Schrott-Fischer

      Affiliations

    • Department of Otorhinolaryngology – Head and Neck Surgery
    • ,
  • N. Romani

      Affiliations

    • Department of Dermatology, University of Innsbruck, Austria
    • ,
  • W.F. Thumfart

      Affiliations

    • Department of Otorhinolaryngology – Head and Neck Surgery

References 

    REFERENCES
  1. Hsu FJ, Benike C, Fagnoni F. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52–58
  2. Nestle FO, Alijagic S, Gilliet M. Vaccination of melanoma patients with pep. Nat Med. 1998;4:328–332
  3. Bodey B, Bodey B, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 2000;20:2665–2676
  4. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994;180:1–4
  5. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525–531
  6. Pardoll DM. Therapeutic vaccination for cancer. Clin Immunol. 2000;95:S44–S62
  7. Agha-Mohammadi S, Lotze MT. Immunomodulation of cancer: potential use of selectively replicating agents. J Clin Invest. 2000;105:1173–1176
  8. Thurner B, Haendle I, Roder C. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669–1678
  9. Panelli MC, Wunderlich J, Jeffries J. Phase 1 study in patients with metastatic melanoma of immunisation with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother. 2000;23:487–498
  10. Schuler-Thurner B, Dieckmann D, Keikavoussi P. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000;165:3492–3496
  11. Salgaller ML, Thurnher M, Bartsch G, Boynton AL, Murphy GP. Report from the International Union Against Cancer (UICC) Tumour Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials. Cancer. 1999;86:2674–2683
  12. Nestle FO, Burg G, Dummer R. New perspectives on immunobiology and immunotherapy of melanoma. Immunol Today. 1999;20:5–7
  13. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;18:245–273
  14. Holtl L, Rieser C, Papesh C. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999;161:777–782
  15. Kugler A, Stuhler G, Walden P. Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids. Nat Med. 2000;6:332–336
  16. Murphy GP, Tjoa BA, Simmons SJ. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate. 1999;38:73–78
  17. Reichardt VL, Okada CY, Liso A. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood. 1999;93:2411–2419
  18. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045
  19. Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest. 1990;85:955–961
  20. Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci USA. 1990;87:7698–7702
  21. O’Doherty U, Steinman RM, Peng M. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med. 1993;178:1067–1078
  22. Romani N, Reider D, Heuer M. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137–151
  23. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor alpha. J Exp Med. 1994;179:1109–1118
  24. Jonuleit H, Kühn U. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135–3142
  25. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA. 1996;93:2588–2592
  26. De Saint-Vis B, Vincent J, Vandenabeele S. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity. 1998;9:325–336
  27. Dhodapkar MV, Steinman RM, Sapp M. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 1999;104:173–180
  28. Thurner B, Roder C, Dieckmann D. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. Immunol Methods. 1999;223:1–15
  29. Zitvogel L, Regnault A, Lozier A. Eradication of established murine tumours using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4:594–600
  30. Mule JJ. Dendritic cells: at the clinical crossroads. J Clin Invest. 2000;105:707–708
  31. Banchereau J, Briere F, Caux C. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811
  32. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? mechanisms of immune evasion by tumours. Immunol Today. 1999;20:158–160
  33. Bennett MW, O’Connell J, O’Sullivan GC. The Fas counterattack in vivo: apoptotic depletion of tumour-in filtrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 1998;160:5669–5675
  34. Trapani JA, Sutton VR, Smyth MJ. CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today. 1999;20:351–356
  35. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today. 1996;17:217–224
  36. Eerola AK, Soini Y, Paakko P. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. Lung Cancer. 1999;26:73–83
  37. Albert ML, Pearce SF, Francisco LM. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359–1368
  38. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumour cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000;191:423–434
  39. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today. 2000;21:403–410
  40. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634–641
  41. Tuting T, Wilson CC, Martin DM. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol. 1998;160:1139–1147
  42. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998;16:364–369
  43. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood. 1998;91:392–398
  44. Scott-Taylor TH, Pettengell R, Clarke I. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta. 2000;1500:265–279
  45. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumour antigens shared with normal host cells results in severe autoimmune disease. J Exp Med. 2000;191:795–804
  46. zur Hansen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690–698
  47. Alters SE, Gadea JR, Sorich M, O’Donoghue G, Talib S, Philip R. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother. 1998;21:17–26
  48. Tjoa BA, Erickson SJ, Bowes VA. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate. 1997;32:272–278
  49. Kim DT, Mitchell DJ, Brockstedt DG. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol. 1997;159:1666–1668
  50. Bittner M, Meltzer P, Chen Y. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536–540
  51. Staudt LM, Brown PO. Genomic views of the immune system. Annu Rev Immunol. 2000;18:829–859
  52. Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Pantel K. The 17–1A antigen is expressed on primary, metastatic and disseminated non-small cell lung carcinoma cells. Int J Cancer. 2000;87:548–552
  53. Pantel K, von Knebel DM. Detection and clinical relevance of micrometastatic cancer cells. Curr Opin Oncol. 2000;12:95–101
  54. Cortesina G, Martone T, Galeazzi E. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumour cells in lymph node metastases. Int J Cancer. 2000;89:286–292
  55. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406:532–535
  56. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91:1113–1124
  57. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 2000;89:2646–2654
  58. Dieu MC, Vanbervliet B, Vicari A. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373–386
  59. Zinkernagel RM. Immunity 2000. Immunol Today. 2000;21:422–423
  60. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252

PII: S0305-7372(01)90221-X

doi: 10.1053/ctrv.2001.0221

Cancer Treatment Reviews
Volume 27, Issue 4 , Pages 247-255 , August 2001

Article Tools